Biophytis to contribute BIO101 patents to Hong Kong joint venture, receive single-digit royalties

• Biophytis will contribute BIO101-related patents in China, Japan, South Korea to its Hong Kong joint venture, paired with a territory license.
• The joint venture will pay Biophytis single-digit royalties on future sales under the license.
• Partners target completion within weeks, subject to administrative clearances, no later than end-September 2026.
• The IP contribution is tied to a first USD 3 million funding tranche into the joint venture, part of up to USD 20 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biophytis SA published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein.